This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: pulmonary arterial hypertension

October 2018 Br J Cardiol 2018;25:135–7 Online First

News from ESC 2018: Is it safe for women with heart disease to become pregnant?

BJC Staff

Abstract

European Society of Cardiology congress 2018, held in Munich Professor Jolien Roos-Hesselink, said: “Pregnancy is safe for most women with heart disease but for some it is too risky. Our study shows that fewer women with heart disease die or have heart failure during pregnancy than 10 years ago. However, nearly one in 10 women with pulmonary arterial hypertension died during pregnancy or early post-partum.” She added that pre-pregnancy counselling is crucial to identify women who should be advised against pregnancy, for instance in those with severe valvular heart disease, and to discuss the risks, options and to initiate timely treatment

| Full text

January 2009 Br J Cardiol 2009;16(Suppl 1):S2-S3

Moving forward in pulmonary arterial hypertension

Henry Purcell

Abstract

Diagnosis can be challenging as its symptoms are often non-specific: they may include breathlessness, fatigue, weakness, angina, syncope and abdominal distension. In the mid-1980s, before the availability of ‘targeted’ therapy, median life expectancy from diagnosis in patients with idiopathic PAH (formerly termed primary pulmonary hypertension [PPH]) was only 2.8 years.3 In 1996, continuous intravenous prostacyclin (epoprostenol) was the first drug to demonstrate outcome benefit in PAH.4 Subsequently, over the past ten years, randomised, placebo-controlled trials of other prostacyclin analogues, endothelin receptor antagonists and phospho

| Full text

January 2009 Br J Cardiol 2009;16(Suppl 1):S10-S12

The optimal time to treat PAH patients

BJCardio editorial team

Abstract

Figure 1: NYHA Functional Class at presentation in pulmonary arterial hypertension (PAH) Despite greater awareness of PAH in recent years and the availability of targeted therapies, the majority of patients are at an advanced symptomatic stage by the time they are diagnosed.3 A French registry of 674 patients has highlighted that 75% of patients were in New York Heart Association (NYHA) Class III or IV at presentation (figure 1).3 Clinical investigations to date have focused largely on these more compromised patient populations. However, some recent studies have included patients in the early symptomatic stages of the disease. This is suppor

| Full text

July 2005 Br J Cardiol (Acute Interv Cardiol) 2005;12:AIC 62–AIC 67

Oral treatments for pulmonary arterial hypertension

Matt J Wright, J Simon R Gibbs

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now